RS67258B1 - Upotreba dugodelujućih glp-1 peptida - Google Patents

Upotreba dugodelujućih glp-1 peptida

Info

Publication number
RS67258B1
RS67258B1 RS20250936A RSP20250936A RS67258B1 RS 67258 B1 RS67258 B1 RS 67258B1 RS 20250936 A RS20250936 A RS 20250936A RS P20250936 A RSP20250936 A RS P20250936A RS 67258 B1 RS67258 B1 RS 67258B1
Authority
RS
Serbia
Prior art keywords
glp
agonist
semaglutide
treatment
agonists
Prior art date
Application number
RS20250936A
Other languages
English (en)
Serbian (sr)
Inventor
Christine Bjørn Jensen
Mads Frederik Rasmussen
Milan Zdravkovic
Peter Kristensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of RS67258B1 publication Critical patent/RS67258B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RS20250936A 2012-07-01 2013-06-21 Upotreba dugodelujućih glp-1 peptida RS67258B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
EP20157813.5A EP3689365B1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (1)

Publication Number Publication Date
RS67258B1 true RS67258B1 (sr) 2025-10-31

Family

ID=65858459

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20250936A RS67258B1 (sr) 2012-07-01 2013-06-21 Upotreba dugodelujućih glp-1 peptida
RS20200684A RS60432B1 (sr) 2012-07-01 2013-06-21 Upotreba glp-1 peptida sa dugim dejstvom

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20200684A RS60432B1 (sr) 2012-07-01 2013-06-21 Upotreba glp-1 peptida sa dugim dejstvom

Country Status (17)

Country Link
US (2) US9764003B2 (https=)
EP (3) EP2866825B1 (https=)
JP (1) JP6059802B2 (https=)
AU (3) AU2013286177B2 (https=)
BR (1) BR112014032938A2 (https=)
CA (1) CA2877056A1 (https=)
DK (1) DK2866825T3 (https=)
ES (2) ES3041720T3 (https=)
HR (2) HRP20200889T1 (https=)
HU (2) HUE072859T2 (https=)
MX (3) MX366405B (https=)
PL (2) PL3689365T3 (https=)
PT (1) PT2866825T (https=)
RS (2) RS67258B1 (https=)
RU (2) RU2018117557A (https=)
SI (1) SI2866825T1 (https=)
WO (1) WO2014005858A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
EP2866825B1 (en) 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
KR102321242B1 (ko) * 2014-10-16 2021-11-02 얀마 파워 테크놀로지 가부시키가이샤 작업 차량
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
CA3078652A1 (en) * 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US20210162013A1 (en) * 2018-08-03 2021-06-03 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
CN113766930B (zh) * 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
IL291876A (en) 2019-11-06 2022-06-01 Novo Nordisk As Receptor agonists in glp-1 type dementia
EP4086277A4 (en) * 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
CN115484935A (zh) 2020-02-14 2022-12-16 G2G生物公司 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
JP2024527528A (ja) * 2021-06-24 2024-07-25 ギラ セラピューティクス インコーポレイテッド 満腹感を誘導する、及び代謝障害を治療するための方法及びキット
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
US20230374096A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
JP2026502943A (ja) 2022-12-30 2026-01-27 アルギファルマ エーエス 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
CN121843690A (zh) 2023-07-24 2026-04-10 莱兰斯坦福初级大学评议会 用于递送治疗性肽的组合物和方法
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
KR102930984B1 (ko) * 2024-01-29 2026-02-25 주식회사 티온랩테라퓨틱스 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
WO2026046328A1 (en) * 2024-08-30 2026-03-05 Beijing Ql Biopharmaceutical Co., Ltd. Dosing regimen of glp-1 conjugates
CN118845644B (zh) * 2024-09-27 2025-01-17 杭州信海医药科技有限公司 一种司美格鲁肽注射液的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
BR122019021416A2 (https=) 2003-09-19 2019-12-21
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
MX2007005521A (es) 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
KR101438839B1 (ko) 2006-04-14 2014-10-02 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
CA2677852A1 (en) 2007-03-20 2008-09-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
AU2010212823B2 (en) * 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
CN102946875A (zh) * 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
EP2866825B1 (en) 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides

Also Published As

Publication number Publication date
US20150190474A1 (en) 2015-07-09
US9764003B2 (en) 2017-09-19
HUE072859T2 (hu) 2025-12-28
DK2866825T3 (da) 2020-06-08
HUE049152T2 (hu) 2020-09-28
HRP20200889T1 (hr) 2020-09-04
WO2014005858A1 (en) 2014-01-09
MX2019008148A (es) 2019-09-05
AU2018202504A1 (en) 2018-05-10
RU2657573C2 (ru) 2018-06-14
AU2020202573A1 (en) 2020-05-07
JP2015522573A (ja) 2015-08-06
AU2013286177B2 (en) 2018-04-26
EP3689365C0 (en) 2025-08-06
EP3689365A1 (en) 2020-08-05
HRP20251088T1 (hr) 2025-11-07
AU2013286177A1 (en) 2015-01-15
EP2866825B1 (en) 2020-04-08
EP4406593A3 (en) 2024-10-23
US20180085435A1 (en) 2018-03-29
RS60432B1 (sr) 2020-07-31
JP6059802B2 (ja) 2017-01-11
SI2866825T1 (sl) 2020-07-31
CA2877056A1 (en) 2014-01-09
AU2020202573B2 (en) 2023-04-20
EP4406593A2 (en) 2024-07-31
US10335462B2 (en) 2019-07-02
ES3041720T3 (en) 2025-11-14
MX376058B (es) 2025-03-07
MX2014014946A (es) 2015-04-08
EP2866825A1 (en) 2015-05-06
PL2866825T3 (pl) 2021-02-22
BR112014032938A2 (pt) 2017-08-01
MX2020010693A (es) 2020-11-06
MX366405B (es) 2019-07-08
PT2866825T (pt) 2020-07-15
AU2018202504B2 (en) 2020-05-07
PL3689365T3 (pl) 2025-11-12
RU2018117557A (ru) 2019-03-22
ES2796839T3 (es) 2020-11-30
RU2015101826A (ru) 2016-08-20
RU2018117557A3 (https=) 2021-08-20
EP3689365B1 (en) 2025-08-06

Similar Documents

Publication Publication Date Title
AU2020202573B2 (en) Use of long-acting GLP-1 peptides
JP5645339B2 (ja) 摂食行動の修正
RU2610175C2 (ru) Новые аналоги глюкагона
CN106715466B (zh) 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽-4衍生物
KR20110021758A (ko) 이형체-특이적 인슐린 유사체
US20160136246A1 (en) Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes
KR20230009499A (ko) 연장된 시간 작용 아실화된 인슐린 화합물
US20110245160A1 (en) Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
Gasbjerg et al. Proglucagon-derived peptides: human physiology and therapeutic potential
CN116113639A (zh) 活性降低的glp-1r激动肽
Chakraborti Exenatide: a new promising antidiabetic agent
US10995129B2 (en) Non-standard insulin analogues
Koshy et al. A review of the efficacy and cardiovascular safety of amylin analogues